Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
1.875
+0.025 (1.35%)
Jun 4, 2025, 1:51 PM - Market open
Outlook Therapeutics Stock Forecast
OTLK's stock price has decreased by -73.83% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Outlook Therapeutics stock ranges from a low of $3.00 to a high of $24. The average analyst price target of $10.2 forecasts a 444.00% increase in the stock price over the next year.
Price Target: $10.20 (+444.00%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 24, 2025.
Analyst Ratings
The average analyst rating for Outlook Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $33 → $24 | Strong Buy | Maintains | $33 → $24 | +1,180.00% | Feb 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $3 | Strong Buy | Maintains | $30 → $3 | +60.00% | Feb 18, 2025 |
| Chardan Capital | Chardan Capital | Hold Maintains $3 | Hold | Maintains | $3 | +60.00% | Feb 18, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +540.00% | Jan 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +1,500.00% | Jan 17, 2025 |
Financial Forecast
Revenue This Year
8.85M
Revenue Next Year
40.18M
from 8.85M
Increased by 354.06%
EPS This Year
-1.89
from -4.06
EPS Next Year
-1.08
from -1.89
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 13.2M | 53.5M | 136.5M | ||
| Avg | 8.8M | 40.2M | 116.9M | ||
| Low | 4.9M | 24.5M | 95.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 504.6% | 239.8% | ||
| Avg | - | 354.1% | 191.0% | ||
| Low | - | 176.9% | 138.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.76 | -1.00 | 1.32 | ||
| Avg | -1.89 | -1.08 | 0.95 | ||
| Low | -3.19 | -1.14 | 0.61 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.